Product Description
Mechanisms of Action: TPO Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Purpura, Thrombocytopenic, Idiopathic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| L4665-03 | P2 |
Completed |
Purpura, Thrombocytopenic, Idiopathic |
2009-05-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/19/2024 |
PubMed |
Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms. |
|
03/14/2024 |
PubMed |
[Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center]. |